[1] Chen Y,Sze J,He ML. HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage. World J Gastroenterol,2004,10:82-85.
[2] Chong CL,Chen ML,Wu YC,et al. Dynamics of HBV cccDNA expression and transcription in different cell growth phase. J Biomed Sci,2011,18（1）:96-112.
[3] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[4] 董南,何波,庄辉. 慢性乙型肝炎患者对疾病和抗病毒治疗的认知程度调查. 肝脏,2009,14（1）:8-10.
[5] Werle-Lapostolle B,Bowden S,Locarnini S,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gasroenterology,2004,126（7）:1750-1758.
[6] Chan HL,Wong VW,Tse AM,et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol,2007,5（12）:1462-1468.
[7] Brunetto MR,Moriconi F,Bonino F,et al. Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology,2009,49（4）:1141-1150.
[8] Rijckborst V,Hansen BE,Cakaloglu Y,et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology,2010,52（2）:454-461.
[9] Gallant JE. Initial therapy of HIV infection. J Clin Virol,2002,25（3）:317-333.
[10] 陈亚丹,绳宇. 艾滋病患者抗病毒药物和资料依从性的干预现状. 中华护理杂志,2010,45（4）:375-377. |
